AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15560363 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week strength-training program
Number of subjects: 16
Study 11490239 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage surgical technique with a scrotal flap
Number of subjects: 34
Study 9738175 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP
Number of subjects: 10271
Study 9738175 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 10271
Study 7985255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7985255 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terbutaline
Number of subjects: 17
Study 7985255 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg terbutaline
Number of subjects: 17
Study 7985255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg terbutaline
Number of subjects: 17
Study 7985255 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of terbutaline (2, 4, and 6 mg)
Number of subjects: 17
Study 2532229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms three times daily)
Number of subjects: 20
Study 2532229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg three times daily)
Number of subjects: 20
Study 1128571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of cholylglycine at a dose of 5 mumoles per kilogram
Number of subjects: 45
Study 31801384 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming/cooling device worn on the wrist for 2 weeks
Number of subjects: 39
Study 31801384 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (no device) for 2 weeks
Number of subjects: 39
Study 30912471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual rehabilitation program (education and exercise)
Number of subjects: 80
Study 30912471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 26236925 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-interferon/ribavirin treatment for 12 weeks followed by 48 weeks for cEVR patients (Group A)
Number of subjects: 438
Study 26236925 — intervention group
Group type: COMPARATOR
Intervention: peg-interferon/ribavirin treatment for 12 weeks followed by 72 weeks (Group B1)
Number of subjects: 438
Study 26236925 — intervention group
Group type: COMPARATOR
Intervention: peg-interferon/ribavirin treatment for 12 weeks followed by 96 weeks (Group B2)
Number of subjects: 438
Study 23179471 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (generic citalopram 20 mg)
Number of subjects: 24
Study 23179471 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (branded citalopram 20 mg)
Number of subjects: 24
Study 23179471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 21502083 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir 900 mg daily for 8 weeks
Number of subjects: 30
Study 21502083 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study 18998160 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with directly marked target locations (no memory required)
Number of subjects: 25
Study 18998160 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition requiring memorization of target locations (SWM)
Number of subjects: 25
Study 18998160 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition requiring retrieval of target locations from LTM (SWM and LTM)
Number of subjects: 25
Study 16554689 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for diabetes self-management
Number of subjects: 0
Study 15817527 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial publications with unclear allocation concealment
Number of subjects: 102
Study 15817527 — intervention group
Group type: COMPARATOR
Intervention: Protocols with adequate allocation concealment
Number of subjects: 102
Study 15817527 — intervention group
Group type: COMPARATOR
Intervention: Protocols with unclear allocation concealment
Number of subjects: 102
Study 15817527 — intervention group
Group type: COMPARATOR
Intervention: Protocols with inadequate allocation concealment
Number of subjects: 102
Study 15817527 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial publications with retrospectively defined loose criteria for concealment
Number of subjects: 102
Study 15817527 — intervention group
Group type: COMPARATOR
Intervention: Protocols with adequate allocation concealment (retrospective criteria)
Number of subjects: 102
Study 15817527 — intervention group
Group type: COMPARATOR
Intervention: Protocols with unclear allocation concealment (retrospective criteria)
Number of subjects: 102
Study 15817527 — intervention group
Group type: COMPARATOR
Intervention: Protocols with inadequate allocation concealment (retrospective criteria)
Number of subjects: 102
Study 12001778 — intervention group
Group type: COMPARATOR
Intervention: Basal and stimulated levels of 17 OH progesterone and androstenedione
Number of subjects: 24
Study 12001778 — intervention group
Group type: COMPARATOR
Intervention: LH/FSH ratio
Number of subjects: 24
Study 10545787 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV) administered as a 14-day continuous infusion according to a flat or three different chronomodulated rhythms
Number of subjects: 113
Study 10545787 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 113
Study 8696436 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ice bag (group I)
Number of subjects: 12
Study 8696436 — intervention group
Group type: EXPERIMENTAL
Intervention: New cooling blanket (group II)
Number of subjects: 12
Study 8696436 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral hands)
Number of subjects: 12
Study 2084084 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 38
Study 2084084 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 38
Study 2084084 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled Hypertensives
Number of subjects: 38
Study 2084084 — intervention group
Group type: COMPARATOR
Intervention: Atenolol vs Captopril
Number of subjects: 38
Study 320494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrium (up to 800 mg for 14‐16 days)
Number of subjects: 20
Study 320494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrium
Number of subjects: 20
Study 320494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30361957 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin with cholecalciferol (group-B)
Number of subjects: 389
Study 30361957 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (group-A)
Number of subjects: 389
Study 28356030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0
Study 28356030 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 0
Study 25974277 — intervention group
Group type: COMPARATOR
Intervention: Control blocks + intravenous (IV) dexamethasone (4 mg)
Number of subjects: 90
Study 25974277 — intervention group
Group type: EXPERIMENTAL
Intervention: Control blocks + IV buprenorphine (150 μg) + IV dexamethasone
Number of subjects: 90
Study 25974277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve blocks containing buprenorphine + dexamethasone (perineural)
Number of subjects: 90
Study 23639299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation practice (3 days a week or more)
Number of subjects: 0
Study 23639299 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness meditation practice (less than 3 days a week)
Number of subjects: 0
Study 23639299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation practice (greater number of days meditated)
Number of subjects: 0
Study 23639299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation practice (minimum of 3 times a week)
Number of subjects: 0
Study 21324172 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (http://www.wiagesprek.nl)
Number of subjects: 123
Study 19205724 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-handed lifts
Number of subjects: 29
Study 19205724 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handed lifts
Number of subjects: 29
Study 19205724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifts at greater distances from the body
Number of subjects: 29
Study 19205724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifts closer to the body
Number of subjects: 29
Study 17056258 — intervention group
Group type: EXPERIMENTAL
Intervention: VR environment
Number of subjects: 10
Study 17056258 — intervention group
Group type: COMPARATOR
Intervention: Non-VR environment
Number of subjects: 10
Study 15046282 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml 30% glucose
Number of subjects: 57
Study 15046282 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 57
Study 11219757 — intervention group
Group type: EXPERIMENTAL
Intervention: Four variants of the subjective workload assessment technique (SWAT) using continuous subscales
Number of subjects: 15
Study 11219757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairwise comparison procedure
Number of subjects: 15
Study 11219757 — intervention group
Group type: COMPARATOR
Intervention: Conventional SWAT scale
Number of subjects: 15
Study 9776154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative irrigation with 10 mL 0.5% bupivacaine in 500 mL saline
Number of subjects: 105
Study 9776154 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 105
Study 7922964 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nurse intervention promoting safety behaviours
Number of subjects: 68
Study 7922964 — intervention group
Group type: COMPARATOR
Intervention: Public health nurse intervention promoting influenza immunization
Number of subjects: 68
Study 3392652 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 12
Study 3392652 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12
Study 3392652 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 12
Study 3392652 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (600 mg)
Number of subjects: 12
Study 3392652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30764710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bringing Baby Home couple‐focused psychoeducational program
Number of subjects: 136
Study 30764710 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 30591394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone substitute (Bio-Oss®) in INTER position
Number of subjects: 25
Study 30591394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone substitute (Bio-Oss®) in ONLAY position
Number of subjects: 25
Study 30591394 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous iliac crest bone grafting
Number of subjects: 25
Study 28988173 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DPCP therapy for up to 12 months
Number of subjects: 30
Study 28988173 — intervention group
Group type: COMPARATOR
Intervention: Topical imiquimod therapy for up to 12 months
Number of subjects: 30
Study 25819865 — intervention group
Group type: EXPERIMENTAL
Intervention: sensitive troponin I (sTnI)
Number of subjects: 322
Study 25819865 — intervention group
Group type: EXPERIMENTAL
Intervention: highly sensitive troponin I (hsTnI)
Number of subjects: 322
Study 25819865 — intervention group
Group type: COMPARATOR
Intervention: conventional troponin (cTn)
Number of subjects: 322
Study 25819865 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI below limit of detection
Number of subjects: 322
Study 22820554 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 64
Study 22820554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21519072 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 87
Study 21519072 — intervention group
Group type: COMPARATOR
Intervention: Open discectomy
Number of subjects: 87
Study 17963038 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy improvement over time
Number of subjects: 170
Study 17963038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to fat gram goal
Number of subjects: 170
Study 17963038 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss after 18 months
Number of subjects: 170
Study 17963038 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy controlling for fat gram adherence
Number of subjects: 170
Study 16922749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (500 mug) prior to anaesthesia and postoperative intravenous patient-controlled analgesia with morphine
Number of subjects: 30
Study 16922749 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intravenous patient-controlled analgesia only
Number of subjects: 30
Study 16145920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with tramadol (Group T)
Number of subjects: 30
Study 16145920 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (Group R)
Number of subjects: 30
Study 17848760 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (50 microg/kg loading dose followed by 100 microg/kg/hr infusion)
Number of subjects: 60
Study 17848760 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (0.15 mg/kg loading dose followed by 5 mg/hr infusion)
Number of subjects: 60
Study 17848760 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60
Study 17848760 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 60
Study 9354209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 20
Study 9354209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg once daily
Number of subjects: 20
Study 8268118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (100 micrograms)
Number of subjects: 40
Study 8268118 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100 micrograms)
Number of subjects: 40
Study 8268118 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for intravenous fentanyl)
Number of subjects: 40
Study 8268118 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for epidural fentanyl)
Number of subjects: 40
Study 3899165 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin pretreatment
Number of subjects: 45
Study 3899165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31717625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 37
Study 31717625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-land exercise
Number of subjects: 37
Study 31717625 — intervention group
Group type: COMPARATOR
Intervention: Aquatic control
Number of subjects: 37
Study 31717625 — intervention group
Group type: COMPARATOR
Intervention: Dry-land control
Number of subjects: 37
Study 29359480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1000 mg omega-3 fatty acids)
Number of subjects: 40
Study 29359480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27590865 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (8 weeks of daily sessions)
Number of subjects: 23
Study 27590865 — intervention group
Group type: COMPARATOR
Intervention: Best current care (control group)
Number of subjects: 23
Study 24846347 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab (doses between 140 and 210 mg)
Number of subjects: 0
Study 24846347 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 0
Study 22318881 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation
Number of subjects: 120
Study 22318881 — intervention group
Group type: COMPARATOR
Intervention: Implantable loop recorder (ILR)
Number of subjects: 120
Study 20371015 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ankle brace (Active Ankle Trainer II)
Number of subjects: 999
Study 20371015 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ankle brace (Aircast Sports Stirrup)
Number of subjects: 999
Study 20371015 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rigid brace (female players)
Number of subjects: 999
Study 20371015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brace)
Number of subjects: 999
Study 18076705 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg subcutaneously once weekly for 12 weeks
Number of subjects: 10
Study 15969895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg
Number of subjects: 168
Study 15969895 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 168
Study 12180075 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic villi sampling (CVS)
Number of subjects: 126
Study 12180075 — intervention group
Group type: COMPARATOR
Intervention: Genetic amniocentesis (GA)
Number of subjects: 126
Study 12180075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical health states
Number of subjects: 126
Study 11529652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg qid
Number of subjects: 8
Study 11529652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10205348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified food and snacks providing an extra 22.2g protein/day and 966 kcal/day
Number of subjects: 144
Study 10205348 — intervention group
Group type: COMPARATOR
Intervention: Control group ate freely from the hospital menu
Number of subjects: 144
Study 7955975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoglycaemia in insulin-dependent diabetic patients
Number of subjects: 22
Study 7955975 — intervention group
Group type: COMPARATOR
Intervention: Reference test with normal plasma glucose levels in insulin-dependent diabetic patients
Number of subjects: 22
Study 7955975 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic subjects
Number of subjects: 22
Study 7955975 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients post-hypoglycaemia
Number of subjects: 22
Study 3616277 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures taken to handle health problems
Number of subjects: 185
Study 3616277 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with social network
Number of subjects: 185
Study 3616277 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with professional medical system
Number of subjects: 185
Study 3616277 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contacts for health problems in children
Number of subjects: 185
Study 3616277 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of treatment within the family
Number of subjects: 185
Study 29019449 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA embolization
Number of subjects: 72
Study 29019449 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 72
Study 28115015 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab therapy
Number of subjects: 0
Study 25707487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (0.2mg/kg/day)
Number of subjects: 0
Study 25707487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (0.15-0.175mg/kg/day) plus basiliximab
Number of subjects: 0
Study 25707487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (0.2mg/kg/day delayed until Day 5) plus basiliximab
Number of subjects: 0
Study 24059134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway (group N)
Number of subjects: 60
Study 24059134 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal airway (group O)
Number of subjects: 60
Study 21733605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation (30g/day, 0.41g/kg/day)
Number of subjects: 33
Study 21733605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30g maltodextrin)
Number of subjects: 33
Study 18654095 — intervention group
Group type: EXPERIMENTAL
Intervention: Second harmonic transthoracic echography with mixture A (dextrose and air)
Number of subjects: 121
Study 18654095 — intervention group
Group type: EXPERIMENTAL
Intervention: Second harmonic transthoracic echography with mixture B (dextrose and air and blood)
Number of subjects: 121
Study 18654095 — intervention group
Group type: EXPERIMENTAL
Intervention: Second harmonic transthoracic echography with mixture C (hydroxyethylamidon)
Number of subjects: 121
Study 18654095 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echography
Number of subjects: 121
Study 16583581 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG electrodes
Number of subjects: 390
Study 16583581 — intervention group
Group type: COMPARATOR
Intervention: BIS electrodes
Number of subjects: 390
Study 12774014 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a plus ribavirin
Number of subjects: 0
Study 12774014 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alpha‐2a alone
Number of subjects: 0
Study 12774014 — intervention group
Group type: EXPERIMENTAL
Intervention: standard interferon alpha‐2b plus ribavirin
Number of subjects: 0
Study 10831546 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 91
Study 10831546 — intervention group
Group type: COMPARATOR
Intervention: highly purified urinary FSH (uFSH)
Number of subjects: 91
Study 9356548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product-free diet
Number of subjects: 18
Study 9356548 — intervention group
Group type: COMPARATOR
Intervention: Dairy product-rich diet
Number of subjects: 18
Study 8412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Remission (CR) in patients treated for advanced Hodgkin's disease
Number of subjects: 560
Study 8412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Survival
Number of subjects: 560
Study 8412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-Free Survival
Number of subjects: 560
Study 8412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Rate to Radiation Therapy in young cohort
Number of subjects: 560